GlassScriptPhysician profile
John Paul Wuennenberg
NPI 1124554589
$1,905.25
in general payments reported to CMS, 2019-2025
18 companies · $680 in 2025
The $680 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $403 · 2021: $92.12 · 2022: $164 · 2023: $218 · 2024: $348 · 2025: $680.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,246.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,245.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $465.82 | 2019-2025 | Skyrizi, Rinvoq |
| Regeneron Healthcare Solutions, INC. | $346.47 | 2019-2025 | Dupixent |
| Lilly USA, LLC | $199.28 | 2022-2025 | Taltz, Ebglyss |
| Amgen INC. | $141.67 | 2022-2025 | Otezla, Otezla |
| Ucb, INC. | $114.88 | 2022-2025 | Bimzelx |
| Genzyme Corporation | $104.76 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $89.28 | 2024-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $85.23 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $84.12 | 2023-2025 | Ilumya |
| Celgene Corporation | $83.83 | 2019 | |
| Kerecis Limited | $36.01 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Smith+Nephew, INC. | $26.76 | 2024 | Grafix Xc |
| Leo Pharma INC. | $26.33 | 2022-2023 | Adbry |
| Janssen Biotech, INC. | $25.26 | 2024 | Tremfya |
| Kyowa Kirin, INC. | $22.18 | 2024 | Poteligeo |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $20.51 | 2023 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.79 | 2023 | Spevigo |
| Krystal Biotech INC | $16.07 | 2025 | Vyjuvek |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Wuennenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.